Company: Baxter International
Beginning price: $50.54
Ending price: $68.81
Baxter International ($BAX) has had issues with infusion pumps, but its drug business--which accounts for about half its revenues--remains solid. It also had about $3 billion in cash sitting on its balance sheet in September, Bloomberg reported. Its share price spiked even higher recently after a rumor surfaced that it was about to spend $4 billion to buy Gambro, one of its key competitors in the kidney dialysis business. If approved, it would round out Baxter's offerings, allow it to cut some costs and remove a competitor from the market.
Baxter posts Q3 growth, but device sales slide
Report: Baxter close to paying $4B for dialysis rival Gambro